Antiemesis

Abstract

Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory. The latest 2009 NCCN Guidelines include updated dosing recommendations for palonosetron and dexamethasone and the inclusion of the granisetron transdermal patch after FDA approval. © Journal of the National Comprehensive Cancer Network.